Treace Medical Concepts reported third quarter 2026 revenue of $48.3 million, a 4% year-over-year decrease that fell short of analyst estimates. However, the company achieved a narrower-than-expected net loss of $0.19 per share and turned Adjusted EBITDA positive for the quarter. The revenue decline was attributed to a shift toward lower-priced minimally invasive products and lower volume from stocking distributors, even as underlying case volumes grew in the double digits.
Key Highlights
- Procedure volume growth accelerated to double digits, driven by increased adoption of the expanded bunion portfolio and SuperBite compression screws.
- Adjusted EBITDA improved by $2.9 million year-over-year to $0.3 million, supported by a 10% reduction in total operating expenses through targeted cost-cutting.
- Year-to-date cash usage was slashed by 53% compared to 2025, leaving the company with $39.8 million in cash and marketable securities.
- Full-year 2026 Adjusted EBITDA loss guidance was improved to a range of $1.0 million to $2.0 million, compared to the previously expected loss of $3.0 million to $5.0 million.